Lab
Sonora Quest Laboratories LLC
Sonora Quest Laboratories LLC was paid $298.05M by Medicaid between Jan 2018 and Dec 2024, across 548 billing codes. Its largest line is U0003, Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r — 27% of everything it billed.
33Billing provider infoSONORA QUEST LABORATORIES LLC
PHOENIX, AZ 85034
PHOENIX, AZ 85034
33aNPI1538105366assigned 06/21/2006
33bProvider typeClinical Medical Laboratory
28Total paid$298.05M
24GClaims28,495,059
24DCodes billed548
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Clinical Medical Laboratory providers in Arizona
Rank by total paid#1 of 67
Median peer was paid$89K
This provider vs. median3,339×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 3,896,464 | $28.69M | |
| 2019 | 4,314,295 | $34.89M | |
| 2020 | 3,553,047 | $46.19M | |
| 2021 | 4,256,026 | $69.28M | |
| 2022 | 4,245,463 | $51.18M | |
| 2023 | 4,067,588 | $34.47M | |
| 2024incomplete | 4,162,176 | $33.36M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 27% | 882,128 | 767,488 | $80.05M |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | 5.5% | 349,662 | 271,851 | $16.30M |
| 80050 | General health panel | 5.1% | 1,143,884 | 1,100,062 | $15.34M |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 4.7% | 473,991 | 368,035 | $14.09M |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | 3.2% | 593,546 | 560,111 | $9.45M |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | 3.1% | 592,788 | 558,295 | $9.37M |
| 80061 | Lipid panel | 3.1% | 1,498,388 | 1,433,703 | $9.35M |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | 2.8% | 757,576 | 726,287 | $8.46M |
| 80053 | Comprehensive metabolic panel | 2.1% | 1,669,027 | 1,453,650 | $6.37M |
| 83036 | Hemoglobin; glycosylated (A1C) | 1.9% | 1,234,745 | 1,182,053 | $5.58M |
| 88175 | Cytopathology, cervical or vaginal, any reporting system; collected in preservative fluid, automated thin layer | 1.6% | 247,585 | 243,562 | $4.89M |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 1.4% | 1,727,852 | 1,465,509 | $4.31M |
536 more codes
| 84443 | Thyroid stimulating hormone (TSH) | 1.3% | 664,758 | $3.93M |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | 1.2% | 283,277 | $3.43M |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | 1.1% | 95,902 | $3.21M |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | 1.0% | 208,316 | $3.12M |
| 87799 | <1% | 70,290 | $2.98M | |
| 36415 | Collection of venous blood by venipuncture | <1% | 1,752,417 | $2.69M |
| 87624 | Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types | <1% | 167,025 | $2.64M |
| 82607 | <1% | 375,184 | $2.64M | |
| 80081 | <1% | 79,827 | $2.56M | |
| 86003 | <1% | 64,869 | $2.22M | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 646,502 | $2.13M |
| 80074 | <1% | 101,218 | $2.06M | |
| 84439 | <1% | 454,701 | $1.92M | |
| 81513 | <1% | 26,077 | $1.77M | |
| 82746 | <1% | 248,029 | $1.72M | |
| 86803 | <1% | 225,660 | $1.69M | |
| 87801 | Infectious agent detection by nucleic acid; amplified probe, multiple organisms | <1% | 47,821 | $1.68M |
| 86769 | <1% | 44,107 | $1.61M | |
| 87902 | <1% | 13,454 | $1.60M | |
| 84403 | <1% | 143,946 | $1.59M | |
| 83013 | <1% | 68,334 | $1.55M | |
| 82728 | <1% | 241,121 | $1.43M | |
| 86481 | <1% | 22,029 | $1.31M | |
| 87088 | <1% | 392,961 | $1.29M | |
| 83970 | <1% | 88,470 | $1.25M | |
| 87481 | <1% | 67,980 | $1.22M | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 26,680 | $1.21M |
| 84153 | <1% | 145,194 | $1.20M | |
| 86480 | <1% | 56,237 | $1.16M | |
| 84481 | <1% | 152,303 | $1.15M | |
| 87522 | Neg quan hep c or qual rna | <1% | 51,926 | $1.12M |
| 87536 | <1% | 25,126 | $1.08M | |
| 86235 | <1% | 43,534 | $1.06M | |
| 87512 | <1% | 62,583 | $978K | |
| 81229 | <1% | 1,349 | $958K | |
| 82670 | <1% | 78,732 | $949K | |
| 84402 | <1% | 85,734 | $890K | |
| 88185 | <1% | 7,615 | $863K | |
| 87636 | Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B | <1% | 7,780 | $862K |
| 82570 | <1% | 420,303 | $858K | |
| 83550 | <1% | 224,992 | $850K | |
| 83540 | <1% | 276,309 | $781K | |
| 83001 | <1% | 88,956 | $772K | |
| 84146 | <1% | 84,411 | $747K | |
| 82043 | <1% | 311,955 | $737K | |
| 87081 | <1% | 256,614 | $695K | |
| 86038 | <1% | 111,433 | $679K | |
| 84702 | <1% | 104,828 | $675K | |
| 86696 | <1% | 72,180 | $666K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 232,274 | $661K |
| 83002 | <1% | 74,441 | $639K | |
| 87077 | <1% | 188,192 | $623K | |
| 83655 | <1% | 117,567 | $618K | |
| 87186 | <1% | 175,831 | $618K | |
| 86592 | <1% | 296,892 | $605K | |
| 88141 | <1% | 34,213 | $605K | |
| G0481 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed | <1% | 10,167 | $585K |
| 87340 | <1% | 142,360 | $584K | |
| 86635 | <1% | 63,306 | $583K | |
| 86140 | <1% | 232,574 | $539K | |
| 87660 | <1% | 66,115 | $531K | |
| 87480 | <1% | 66,130 | $525K | |
| 87510 | <1% | 65,865 | $520K | |
| 81220 | CFTR (cystic fibrosis transmembrane conductance regulator) gene analysis; common variants | <1% | 1,976 | $498K |
| 83735 | <1% | 177,681 | $470K | |
| 86376 | <1% | 64,996 | $447K | |
| 82784 | <1% | 85,841 | $438K | |
| 81003 | <1% | 436,676 | $428K | |
| 86695 | <1% | 63,611 | $400K | |
| 85027 | <1% | 132,466 | $370K | |
| 82105 | <1% | 55,822 | $365K | |
| 86706 | <1% | 76,676 | $364K | |
| 84144 | <1% | 37,341 | $361K | |
| 88342 | <1% | 10,817 | $358K | |
| 83516 | <1% | 35,653 | $352K | |
| 82627 | <1% | 33,626 | $336K | |
| 86800 | <1% | 48,515 | $329K | |
| 83880 | <1% | 24,704 | $326K | |
| 86147 | <1% | 12,186 | $325K | |
| 80164 | <1% | 44,486 | $314K | |
| 86704 | <1% | 60,464 | $313K | |
| 84436 | <1% | 88,740 | $306K | |
| 88184 | <1% | 8,006 | $306K | |
| 85652 | <1% | 253,842 | $304K | |
| 86200 | <1% | 44,416 | $294K | |
| 86160 | <1% | 27,282 | $285K | |
| 86225 | <1% | 40,334 | $278K | |
| 82652 | <1% | 20,835 | $273K | |
| 82785 | <1% | 31,431 | $263K | |
| 86708 | <1% | 39,425 | $257K | |
| 86780 | <1% | 32,974 | $254K | |
| 81001 | <1% | 210,133 | $250K | |
| 84480 | <1% | 35,598 | $248K | |
| 83525 | <1% | 54,838 | $243K | |
| 84154 | <1% | 30,272 | $240K | |
| 85610 | <1% | 159,262 | $234K | |
| 80069 | <1% | 77,458 | $232K | |
| 86146 | <1% | 8,709 | $227K | |
| 84550 | <1% | 120,423 | $222K | |
| 84466 | <1% | 40,738 | $218K | |
| 88341 | <1% | 4,028 | $213K | |
| 82378 | <1% | 27,137 | $212K | |
| 82977 | <1% | 65,886 | $207K | |
| 86431 | <1% | 72,655 | $207K | |
| 83615 | <1% | 83,268 | $205K | |
| 80202 | <1% | 23,558 | $198K | |
| 81596 | <1% | 4,816 | $198K | |
| 86665 | <1% | 14,601 | $195K | |
| 87529 | <1% | 12,422 | $193K | |
| 87631 | <1% | 3,977 | $190K | |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | <1% | 1,347 | $190K |
| 87070 | <1% | 57,342 | $189K | |
| 88112 | <1% | 10,238 | $187K | |
| 87901 | <1% | 1,553 | $186K | |
| 83690 | <1% | 54,851 | $186K | |
| 88312 | <1% | 5,666 | $186K | |
| 84681 | <1% | 21,822 | $183K | |
| 82533 | <1% | 25,304 | $183K | |
| 82950 | <1% | 86,680 | $181K | |
| 82248 | <1% | 82,300 | $181K | |
| 82024 | <1% | 13,084 | $180K | |
| 86364 | <1% | 22,709 | $178K | |
| 84445 | <1% | 9,176 | $176K | |
| 86360 | <1% | 13,174 | $176K | |
| 84100 | <1% | 106,090 | $174K | |
| 86300 | <1% | 17,260 | $173K | |
| 80076 | <1% | 60,190 | $172K | |
| 87209 | <1% | 21,092 | $165K | |
| 82672 | <1% | 17,058 | $165K | |
| 83520 | <1% | 21,710 | $163K | |
| 85730 | <1% | 57,163 | $162K | |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 9,947 | $161K |
| 84156 | <1% | 118,875 | $161K | |
| 88307 | <1% | 1,200 | $159K | |
| P9604 | Travel allowance one way in connection with medically necessary laboratory specimen collection drawn from home bound or nursing home bound patient; prorated trip charge | <1% | 13,348 | $157K |
| 87625 | <1% | 11,533 | $157K | |
| 86361 | <1% | 12,371 | $149K | |
| 84425 | <1% | 15,939 | $148K | |
| 80197 | <1% | 29,304 | $144K | |
| 84479 | <1% | 45,212 | $144K | |
| 87338 | <1% | 23,389 | $143K | |
| 86762 | <1% | 21,104 | $142K | |
| 84270 | <1% | 15,425 | $141K | |
| 86359 | <1% | 12,904 | $139K | |
| 82274 | <1% | 21,483 | $139K | |
| 86141 | <1% | 23,164 | $133K | |
| 86787 | <1% | 23,290 | $132K | |
| 82550 | <1% | 44,171 | $129K | |
| 88189 | <1% | 2,760 | $127K | |
| 82150 | <1% | 39,429 | $126K | |
| 82677 | <1% | 10,089 | $122K | |
| 86304 | <1% | 13,354 | $122K | |
| 86258 | <1% | 14,673 | $119K | |
| 81206 | <1% | 1,679 | $119K | |
| 80055 | <1% | 5,745 | $117K | |
| 86334 | <1% | 11,609 | $112K | |
| 87517 | <1% | 7,491 | $111K | |
| 82951 | <1% | 24,319 | $110K | |
| 84165 | <1% | 23,287 | $109K | |
| 83014 | <1% | 30,907 | $108K | |
| 84432 | <1% | 13,970 | $105K | |
| 86850 | <1% | 43,278 | $104K | |
| 88142 | <1% | 8,046 | $99K | |
| 86705 | <1% | 23,094 | $99K | |
| 86039 | <1% | 16,737 | $99K | |
| 83498 | <1% | 8,637 | $98K | |
| 87497 | <1% | 6,668 | $98K | |
| 87147 | <1% | 50,175 | $97K | |
| 87427 | <1% | 18,265 | $95K | |
| 86317 | <1% | 14,359 | $94K | |
| G0328 | Colorectal cancer screening; fecal occult blood test, immunoassay, 1-3 simultaneous | <1% | 21,629 | $93K |
| 83921 | <1% | 12,785 | $91K | |
| 86255 | <1% | 15,099 | $91K | |
| 87900 | <1% | 1,482 | $91K | |
| 82140 | <1% | 15,990 | $89K | |
| 82088 | <1% | 5,568 | $88K | |
| 82247 | <1% | 40,188 | $85K | |
| 84207 | <1% | 7,953 | $84K | |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 1,826 | $83K |
| 87046 | <1% | 19,018 | $83K | |
| 88304 | <1% | 7,827 | $82K | |
| 87177 | <1% | 20,676 | $81K | |
| 86709 | <1% | 13,821 | $80K | |
| 85060 | <1% | 9,698 | $78K | |
| 84482 | <1% | 10,484 | $78K | |
| 87045 | <1% | 19,038 | $78K | |
| 83993 | <1% | 10,268 | $77K | |
| 86870 | <1% | 3,348 | $77K | |
| 86381 | <1% | 5,477 | $75K | |
| 87205 | <1% | 45,667 | $75K | |
| 86664 | <1% | 8,880 | $75K | |
| 83090 | <1% | 10,329 | $74K | |
| 84630 | <1% | 14,252 | $74K | |
| 84460 | <1% | 36,359 | $71K | |
| 86812 | <1% | 7,516 | $71K | |
| 80178 | <1% | 24,092 | $68K | |
| 88230 | <1% | 1,341 | $67K | |
| 86336 | <1% | 9,576 | $67K | |
| 83704 | <1% | 6,593 | $66K | |
| 82330 | <1% | 12,534 | $63K | |
| 82172 | <1% | 6,384 | $63K | |
| 87075 | <1% | 16,328 | $62K | |
| 88262 | <1% | 1,344 | $62K | |
| 84134 | <1% | 10,150 | $62K | |
| 84305 | <1% | 8,417 | $61K | |
| 84703 | <1% | 16,528 | $61K | |
| 82542 | <1% | 7,916 | $61K | |
| 81241 | <1% | 3,046 | $59K | |
| 86021 | <1% | 14,976 | $59K | |
| 82103 | <1% | 9,197 | $59K | |
| 82626 | <1% | 4,750 | $58K | |
| 86301 | <1% | 6,602 | $57K | |
| 81025 | <1% | 15,894 | $57K | |
| 82390 | <1% | 10,516 | $57K | |
| 87350 | <1% | 10,353 | $56K | |
| 84450 | <1% | 28,436 | $55K | |
| 0225U | <1% | 771 | $54K | |
| 86765 | <1% | 9,012 | $53K | |
| 86320 | <1% | 4,493 | $53K | |
| 87255 | <1% | 3,723 | $53K | |
| 86707 | <1% | 9,559 | $52K | |
| 86015 | <1% | 6,223 | $52K | |
| 80159 | <1% | 7,645 | $52K | |
| 84244 | <1% | 5,091 | $49K | |
| 86341 | <1% | 6,908 | $48K | |
| 82107 | <1% | 2,210 | $48K | |
| 82525 | <1% | 8,360 | $48K | |
| 86900 | <1% | 40,714 | $48K | |
| 82157 | <1% | 3,524 | $48K | |
| 86735 | <1% | 8,158 | $47K | |
| 86901 | <1% | 40,290 | $47K | |
| 83883 | <1% | 6,184 | $47K | |
| 87493 | <1% | 3,617 | $47K | |
| 85245 | <1% | 5,055 | $46K | |
| 82947 | <1% | 25,708 | $46K | |
| 85246 | <1% | 5,017 | $46K | |
| 85379 | <1% | 10,709 | $46K | |
| 85018 | <1% | 48,636 | $45K | |
| 83519 | <1% | 6,941 | $45K | |
| 83521 | <1% | 7,671 | $45K | |
| 84590 | <1% | 8,865 | $43K | |
| 82565 | <1% | 23,815 | $43K | |
| 36416 | <1% | 41,297 | $42K | |
| 80177 | <1% | 7,979 | $41K | |
| 87040 | <1% | 9,413 | $40K | |
| 85045 | <1% | 25,365 | $40K | |
| 84478 | <1% | 19,454 | $40K | |
| 85240 | <1% | 5,031 | $39K | |
| 80156 | <1% | 5,751 | $38K | |
| 82653 | <1% | 2,140 | $38K | |
| 85613 | <1% | 7,302 | $38K | |
| 81243 | <1% | 845 | $38K | |
| 87324 | <1% | 8,182 | $37K | |
| 81420 | Fetal chromosomal aneuploidy genomic sequence analysis panel | <1% | 377 | $37K |
| 86645 | <1% | 4,115 | $36K | |
| 85014 | <1% | 40,780 | $36K | |
| 82668 | <1% | 4,138 | $36K | |
| 82952 | <1% | 20,131 | $35K | |
| 82530 | <1% | 4,806 | $34K | |
| 86738 | <1% | 3,440 | $33K | |
| 86335 | <1% | 3,405 | $33K | |
| 86644 | <1% | 4,245 | $32K | |
| 84166 | <1% | 3,974 | $31K | |
| 83021 | <1% | 4,661 | $30K | |
| 81270 | <1% | 949 | $29K | |
| 83010 | <1% | 5,874 | $29K | |
| 82040 | <1% | 16,846 | $29K | |
| 86593 | <1% | 11,847 | $28K | |
| 86036 | <1% | 1,968 | $28K | |
| 81240 | <1% | 1,991 | $28K | |
| 82787 | <1% | 2,792 | $28K | |
| 82610 | <1% | 5,231 | $28K | |
| 82985 | <1% | 7,091 | $28K | |
| 84155 | <1% | 21,589 | $27K | |
| 86060 | <1% | 7,199 | $27K | |
| 83835 | <1% | 3,876 | $26K | |
| 87329 | <1% | 5,270 | $26K | |
| 81256 | <1% | 1,415 | $26K | |
| 84378 | <1% | 9,148 | $25K | |
| 81015 | <1% | 20,737 | $25K | |
| 82731 | <1% | 1,572 | $25K | |
| 82397 | <1% | 4,613 | $24K | |
| 84520 | <1% | 18,506 | $24K | |
| 83630 | <1% | 2,834 | $24K | |
| 86617 | <1% | 1,930 | $24K | |
| 82310 | <1% | 14,556 | $24K | |
| 84075 | <1% | 13,517 | $24K | |
| 82232 | <1% | 3,447 | $23K | |
| 84446 | <1% | 4,584 | $23K | |
| 83020 | <1% | 4,448 | $23K | |
| 83695 | <1% | 3,891 | $23K | |
| 86162 | <1% | 2,473 | $23K | |
| 82085 | <1% | 5,255 | $22K | |
| 87102 | <1% | 6,715 | $22K | |
| 87563 | <1% | 1,569 | $22K | |
| 80175 | <1% | 3,865 | $22K | |
| 86357 | <1% | 1,273 | $21K | |
| 87210 | <1% | 6,102 | $21K | |
| 86355 | <1% | 1,246 | $21K | |
| 86777 | <1% | 2,573 | $20K | |
| 82104 | <1% | 2,982 | $20K | |
| 85306 | <1% | 2,742 | $20K | |
| 87511 | <1% | 2,338 | $19K | |
| 82679 | <1% | 1,821 | $19K | |
| 86337 | <1% | 1,729 | $19K | |
| 81207 | <1% | 293 | $19K | |
| 83698 | <1% | 1,799 | $18K | |
| 83003 | <1% | 2,356 | $18K | |
| 82384 | <1% | 2,038 | $18K | |
| 84163 | <1% | 4,013 | $17K | |
| 88291 | <1% | 1,671 | $17K | |
| 82747 | <1% | 2,358 | $17K | |
| 85303 | <1% | 2,507 | $17K | |
| 82465 | <1% | 10,837 | $17K | |
| 81479 | Unlisted molecular pathology procedure | <1% | 62 | $17K |
| 86615 | <1% | 2,201 | $17K | |
| 88173 | <1% | 356 | $17K | |
| 82164 | <1% | 2,770 | $17K | |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 2,198 | $17K |
| 85007 | <1% | 12,359 | $17K | |
| 84255 | <1% | 2,374 | $17K | |
| 86663 | <1% | 2,630 | $16K | |
| 87254 | <1% | 1,504 | $16K | |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 386 | $16K |
| 86008 | <1% | 1,562 | $16K | |
| 80185 | <1% | 3,250 | $15K | |
| 87535 | <1% | 1,146 | $15K | |
| 80183 | <1% | 2,484 | $15K | |
| 82239 | <1% | 2,214 | $15K | |
| 86001 | <1% | 2,214 | $15K | |
| 83721 | <1% | 8,253 | $14K | |
| 82575 | <1% | 3,378 | $14K | |
| 84484 | <1% | 3,673 | $14K | |
| 85004 | <1% | 5,733 | $14K | |
| 80158 | <1% | 1,537 | $14K | |
| G0483 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed | <1% | 155 | $14K |
| 86671 | <1% | 1,904 | $14K | |
| 86231 | <1% | 1,167 | $14K | |
| 87109 | <1% | 1,735 | $13K | |
| 86148 | <1% | 3,620 | $13K | |
| 80051 | <1% | 5,110 | $13K | |
| 85300 | <1% | 2,187 | $13K | |
| 86308 | <1% | 4,496 | $13K | |
| 87015 | <1% | 5,150 | $12K | |
| 84080 | <1% | 2,206 | $12K | |
| 85384 | <1% | 3,306 | $12K | |
| 84132 | <1% | 6,917 | $12K | |
| 86316 | <1% | 1,624 | $12K | |
| 87184 | <1% | 4,517 | $12K | |
| 86774 | <1% | 1,718 | $12K | |
| 87269 | <1% | 2,506 | $11K | |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 18,579 | $11K |
| 86778 | <1% | 1,654 | $11K | |
| 87272 | <1% | 2,509 | $11K | |
| 82507 | <1% | 1,172 | $11K | |
| 81050 | <1% | 8,589 | $11K | |
| 87507 | <1% | 65 | $11K | |
| 84597 | <1% | 1,504 | $11K | |
| 80195 | <1% | 2,248 | $11K | |
| 80299 | <1% | 1,796 | $11K | |
| 85041 | <1% | 10,425 | $11K | |
| 82657 | <1% | 898 | $10K | |
| 83605 | <1% | 2,165 | $10K | |
| 82139 | <1% | 1,587 | $10K | |
| 85305 | <1% | 1,735 | $10K | |
| 87521 | Neg quan hep c or qual rna | <1% | 642 | $10K |
| 86618 | <1% | 1,140 | $9K | |
| 87116 | <1% | 2,550 | $9K | |
| 84140 | <1% | 1,133 | $9K | |
| 84300 | <1% | 4,852 | $9K | |
| 84442 | <1% | 966 | $9K | |
| 83935 | <1% | 3,546 | $9K | |
| 81291 | <1% | 739 | $9K | |
| 82671 | <1% | 668 | $9K | |
| 82379 | <1% | 1,630 | $8K | |
| 86256 | <1% | 1,482 | $8K | |
| 86694 | <1% | 1,050 | $8K | |
| 83718 | <1% | 2,531 | $8K | |
| 88313 | <1% | 434 | $8K | |
| 86077 | <1% | 557 | $8K | |
| 87076 | <1% | 2,123 | $7K | |
| 85048 | <1% | 7,276 | $7K | |
| 82664 | <1% | 557 | $7K | |
| 87906 | <1% | 128 | $7K | |
| 82175 | <1% | 802 | $7K | |
| 82340 | <1% | 2,940 | $7K | |
| 86702 | <1% | 1,362 | $7K | |
| 83876 | <1% | 939 | $7K | |
| 83631 | <1% | 860 | $7K | |
| 87206 | <1% | 3,776 | $7K | |
| 84145 | <1% | 1,102 | $7K | |
| 82552 | <1% | 1,234 | $6K | |
| 83945 | <1% | 1,265 | $6K | |
| 83930 | <1% | 2,606 | $6K | |
| 82308 | <1% | 702 | $6K | |
| 83527 | <1% | 1,161 | $6K | |
| 81332 | <1% | 329 | $6K | |
| 87300 | <1% | 1,106 | $6K | |
| 84295 | <1% | 3,838 | $6K | |
| 82365 | <1% | 1,205 | $5K | |
| 80203 | <1% | 1,098 | $5K | |
| 88271 | <1% | 314 | $5K | |
| 80180 | <1% | 755 | $5K | |
| 85247 | <1% | 675 | $5K | |
| 87107 | <1% | 1,194 | $5K | |
| G0472 | Hepatitis c antibody screening, for individual at high risk and other covered indication(s) | <1% | 1,379 | $5K |
| 81403 | <1% | 148 | $5K | |
| 85670 | <1% | 1,844 | $5K | |
| 80162 | <1% | 1,158 | $5K | |
| 85302 | <1% | 872 | $5K | |
| 85660 | <1% | 1,784 | $5K | |
| 86880 | <1% | 1,919 | $5K | |
| 85049 | <1% | 2,793 | $5K | |
| 86340 | <1% | 794 | $5K | |
| 86701 | <1% | 1,357 | $4K | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 787 | $4K |
| 87252 | <1% | 368 | $4K | |
| 82656 | <1% | 811 | $4K | |
| 83825 | <1% | 602 | $4K | |
| 82272 | <1% | 3,165 | $4K | |
| 83874 | <1% | 1,127 | $4K | |
| 88120 | <1% | 12 | $4K | |
| 81450 | <1% | 32 | $4K | |
| 86747 | <1% | 389 | $4K | |
| 84133 | <1% | 2,149 | $4K | |
| 82435 | <1% | 2,128 | $4K | |
| 83088 | <1% | 222 | $4K | |
| 82166 | <1% | 156 | $4K | |
| 82941 | <1% | 645 | $4K | |
| 84588 | <1% | 213 | $4K | |
| G0482 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 15-21 drug class(es), including metabolite(s) if performed | <1% | 66 | $3K |
| 87280 | <1% | 608 | $3K | |
| 87140 | <1% | 1,285 | $3K | |
| 88275 | <1% | 242 | $3K | |
| 80165 | <1% | 709 | $3K | |
| 80201 | <1% | 657 | $3K | |
| G0103 | Prostate cancer screening; prostate specific antigen test (psa) | <1% | 7,516 | $3K |
| 84105 | <1% | 1,392 | $3K | |
| 87807 | <1% | 663 | $3K | |
| 81402 | <1% | 100 | $3K | |
| 84560 | <1% | 1,470 | $3K | |
| 84260 | <1% | 187 | $3K | |
| 82705 | <1% | 1,207 | $3K | |
| 82955 | <1% | 559 | $3K | |
| 80184 | <1% | 657 | $3K | |
| 83986 | <1% | 1,912 | $2K | |
| 87275 | <1% | 444 | $2K | |
| 86606 | <1% | 464 | $2K | |
| 82017 | <1% | 357 | $2K | |
| 87650 | <1% | 413 | $2K | |
| 87341 | <1% | 662 | $2K | |
| 86648 | <1% | 364 | $2K | |
| 82523 | <1% | 373 | $2K | |
| 86832 | <1% | 64 | $2K | |
| 82180 | <1% | 571 | $2K | |
| 82270 | <1% | 1,629 | $2K | |
| 87276 | <1% | 468 | $2K | |
| 84238 | <1% | 88 | $2K | |
| 84252 | <1% | 235 | $2K | |
| 85810 | <1% | 359 | $2K | |
| 83918 | <1% | 243 | $2K | |
| 88344 | <1% | 29 | $2K | |
| 89321 | <1% | 356 | $2K | |
| 82553 | <1% | 466 | $2K | |
| 87101 | <1% | 515 | $2K | |
| 89051 | <1% | 672 | $1K | |
| 84392 | <1% | 777 | $1K | |
| 80235 | <1% | 150 | $1K | |
| 88302 | <1% | 53 | $1K | |
| 86343 | <1% | 202 | $1K | |
| 86161 | <1% | 204 | $1K | |
| 85046 | <1% | 390 | $1K | |
| 84585 | <1% | 173 | $1K | |
| 87425 | <1% | 201 | $1K | |
| 81517 | <1% | 43 | $1K | |
| 84311 | <1% | 286 | $908.20 | |
| 89060 | <1% | 363 | $868.88 | |
| 86788 | <1% | 131 | $843.56 | |
| 81376 | <1% | 13 | $758.60 | |
| 81381 | <1% | 24 | $754.52 | |
| 81219 | <1% | 32 | $746.59 | |
| 87106 | <1% | 166 | $744.76 | |
| 86789 | <1% | 125 | $720.44 | |
| 86403 | <1% | 116 | $699.17 | |
| 86631 | <1% | 111 | $681.20 | |
| 87207 | <1% | 155 | $671.89 | |
| 85999 | <1% | 187 | $641.57 | |
| 83951 | <1% | 139 | $631.02 | |
| 87260 | <1% | 132 | $620.13 | |
| 86632 | <1% | 114 | $608.23 | |
| 88237 | <1% | 12 | $519.24 | |
| 86828 | <1% | 72 | $505.16 | |
| G2023 | Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 62 | $492.66 |
| 85055 | <1% | 44 | $490.82 | |
| 82595 | <1% | 229 | $482.65 | |
| 85301 | <1% | 97 | $457.41 | |
| 86682 | <1% | 44 | $455.46 | |
| 86833 | <1% | 27 | $434.90 | |
| 87279 | <1% | 165 | $433.68 | |
| 84143 | <1% | 28 | $408.32 | |
| 85520 | <1% | 46 | $329.69 | |
| 85307 | <1% | 48 | $294.57 | |
| 82945 | <1% | 154 | $285.87 | |
| 82540 | <1% | 128 | $248.90 | |
| 88264 | <1% | 12 | $235.80 | |
| 82010 | <1% | 93 | $233.62 | |
| 80186 | <1% | 35 | $227.66 | |
| 86790 | <1% | 28 | $221.81 | |
| 86710 | <1% | 29 | $215.61 | |
| 82681 | <1% | 14 | $205.56 | |
| 83497 | <1% | 42 | $192.49 | |
| 86611 | <1% | 28 | $180.58 | |
| 82374 | <1% | 245 | $172.52 | |
| 82495 | <1% | 30 | $170.84 | |
| G0471 | Collection of venous blood by venipuncture or urine sample by catheterization from an individual in a skilled nursing facility (snf) or by a laboratory on behalf of a home health agency (hha) | <1% | 382 | $169.01 |
| 85732 | <1% | 27 | $158.14 | |
| 85250 | <1% | 30 | $154.04 | |
| 85576 | <1% | 12 | $146.04 | |
| 86005 | <1% | 318 | $142.26 | |
| G0145 | Screening cytopathology, cervical or vaginal (any reporting system), collected in preservative fluid, automated thin layer preparation, with screening by automated system and manual rescreening under physician supervision | <1% | 113 | $125.77 |
| 87220 | <1% | 83 | $113.61 | |
| 81382 | <1% | 14 | $108.21 | |
| 86628 | <1% | 12 | $102.37 | |
| 99199 | Unlisted special service, procedure or report | <1% | 3,972 | $100.45 |
| 87273 | <1% | 14 | $80.42 | |
| 87176 | <1% | 43 | $75.19 | |
| 80169 | <1% | 24 | $68.97 | |
| 88164 | <1% | 12 | $58.88 | |
| 87110 | <1% | 12 | $49.89 | |
| 87265 | <1% | 13 | $47.50 | |
| 86886 | <1% | 13 | $37.72 | |
| 87185 | <1% | 13 | $26.74 | |
| 82436 | <1% | 12 | $8.84 | |
| 81508 | 0% | 296 | $0.00 | |
| G0475 | Hiv antigen/antibody, combination assay, screening | 0% | 32 | $0.00 |
| 99001 | 0% | 17 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialDEXTER, DAVID (PRESIDENT/CEO)
Parent organizationQUEST DIAGNOSTICS CLINICAL LABORATORIES INC
| Provider | Location | Paid |
|---|---|---|
| David J Dexter Od PC | Pulaski, NY | $41K |
| David J. Dexter, O.D., P.C. | Oswego, NY | $4K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.